People In Health Care
Professor Rosemary Harrup, Tasmania
Rosemary Harrup trained in Victoria and Tasmania in Medical Oncology and Clinical Haematology, completing a dual Fellowship in 2001. She is the current Director of Cancer and Blood Services at the Royal Hobart Hospital (RHH), a role she has held since 2009.
External to the RHH she is a member of the board of the Cancer Council of Tasmania, the Tasmanian Cancer Registry Advisory Group and the RHH Research Foundation Scientific and Advisory Committee.
Rosemary is currently Deputy Chair of the Cooperative Trials Group for Neuro oncology (COGNO), a member of the Australian Brain Cancer Mission Steering Committee and the Australian Cancer Plan Tasmanian jurisdictional representative. She has a strong interest in clinical research, particularly in the areas of Clinical Trials in Brain Cancer, Malignant Haematology and Late Effects and is an active mentor for early career researchers.
Australian Health Journal spoke to Rosemary about her journey in medicine and specifically her work in Clinical Trials in Brain Cancer and the value she placed on her senior clinicians as mentors and how she now mentors others.
-
New option for management of high-risk soft tissue sarcoma of the limb
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
-
Smart diaper wins Kerrin Rennie technology award
In October 2022, Smartz won the Kerrin Rennie Award for Excellence in Medical Technology – Improving Quality of Life. The award was established to recognise and profile the innovative and extraordinary contribution of medical technology in improving health outcomes of Australian patients.
Smartz monitors patient wellness including 2 significant issues affecting the elderly in residential aged care facilities; incontinence and pressure injuries.
-
Foundation outlines breast cancer research strategy
Australian Health Journal met with Associate Professor Cleola Anderiesz, CEO of the National Breast Cancer Foundation to hear of the new 5 year Pink Horizon research strategy. Those with lived experience of breast cancer, along with researchers, clinicians, and other funding organisations, have contributed to the development of the foundation’s new five-year Pink Horizon research strategy. This ambitious plan aims to invest $125 million to accelerate research efforts towards the vision of ending deaths from breast cancer.
